Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) involves substantial changes in lipid metabolism alongside amyloid-β (Aβ) deposition and tau pathology. The pattern of lipid disruption differs across neural cell types, metabolic pathways, and stages of disease. Here, we focus on three related features: lipid droplet (LD) accumulation, altered cholesterol homeostasis, and abnormal fatty acid metabolism in neurons and glial cells. Although closely related, these changes affect different aspects of cellular lipid handling. LD dynamics influence lipid storage and mobilization, whereas cholesterol and fatty acid abnormalities alter the availability, utilization, and turnover of lipids. The consequences are not necessarily the same across cell types or metabolic states. Some changes may help cells adapt to lipid or metabolic stress, while others are associated with impaired lipid handling and cellular dysfunction. Lipid dysregulation also interacts with AD pathology in both directions. Aβ and tau can alter lipid metabolism, and disturbances in LD dynamics, cholesterol homeostasis, and fatty acid metabolism may themselves affect AD-related pathological processes. Whether these changes are adaptive, detrimental, or both may depend on the cell type and stage of disease. We also consider therapeutic strategies directed at these three aspects of lipid metabolism, including the limitations that need to be addressed before clinical translation.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: